[
  {
    "ts": null,
    "headline": "Sangamo Plunges After Pfizer Ends Pact for Hemophilia Treatment",
    "summary": "(Bloomberg) -- Sangamo Therapeutics Inc. fell as much as 67% in extended trading after Pfizer Inc. ended its partnership to develop a new gene therapy to treat hemophilia A. Most Read from BloombergMigrant Crisis Pushed US Homelessness to Record High in 2024Sangamo is considering “all options” to continue developing the drug, including finding a new partner, the company said in a statement Monday. The experimental medicine met its goal in a pivotal late-stage trial, and Sangamo said Pfizer had p",
    "url": "https://finnhub.io/api/news?id=81a49733427a3563e29ea73c3379a2faabafcda681421dc89655226da07409d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735597880,
      "headline": "Sangamo Plunges After Pfizer Ends Pact for Hemophilia Treatment",
      "id": 132211953,
      "image": "https://s.yimg.com/ny/api/res/1.2/cdWcdTdvOy24wS8U3Kqd1g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/f17eef5397006582b1a35824d8b74c6f",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Sangamo Therapeutics Inc. fell as much as 67% in extended trading after Pfizer Inc. ended its partnership to develop a new gene therapy to treat hemophilia A. Most Read from BloombergMigrant Crisis Pushed US Homelessness to Record High in 2024Sangamo is considering “all options” to continue developing the drug, including finding a new partner, the company said in a statement Monday. The experimental medicine met its goal in a pivotal late-stage trial, and Sangamo said Pfizer had p",
      "url": "https://finnhub.io/api/news?id=81a49733427a3563e29ea73c3379a2faabafcda681421dc89655226da07409d8"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) the Best Pharma Dividend Stock to Buy In 2024?",
    "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower […]",
    "url": "https://finnhub.io/api/news?id=8bb708f8336ab23197cb7aae6995a12908873d27e91db950609960a4faa9ffc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735597564,
      "headline": "Is Pfizer Inc. (PFE) the Best Pharma Dividend Stock to Buy In 2024?",
      "id": 132211954,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower […]",
      "url": "https://finnhub.io/api/news?id=8bb708f8336ab23197cb7aae6995a12908873d27e91db950609960a4faa9ffc9"
    }
  },
  {
    "ts": null,
    "headline": "5 Value Stocks That Could Get a Bump From Activist Investors",
    "summary": "Fund manager Jonathan Boyar and his team highlighted several stocks that could get a boost thanks to activist shareholders.",
    "url": "https://finnhub.io/api/news?id=2daa17806e3161975189cec908f555ae2c478acd165c241a9dc27e515a91e2d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735590720,
      "headline": "5 Value Stocks That Could Get a Bump From Activist Investors",
      "id": 132207955,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Fund manager Jonathan Boyar and his team highlighted several stocks that could get a boost thanks to activist shareholders.",
      "url": "https://finnhub.io/api/news?id=2daa17806e3161975189cec908f555ae2c478acd165c241a9dc27e515a91e2d9"
    }
  },
  {
    "ts": null,
    "headline": "Chevron, Kimberly-Clark Among 15 Companies To Announce Dividend Increases In January",
    "summary": "Get the scoop on upcoming dividend increases from companies with long-term growth histories, including modest increases from Chevron and Kimberly-Clark in...",
    "url": "https://finnhub.io/api/news?id=bc456e33e15cf76dcaa8b97d53d4313285e1d1e774bdc8090f51d5d1802a753a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735585359,
      "headline": "Chevron, Kimberly-Clark Among 15 Companies To Announce Dividend Increases In January",
      "id": 132207437,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/459000811/image_459000811.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Get the scoop on upcoming dividend increases from companies with long-term growth histories, including modest increases from Chevron and Kimberly-Clark in...",
      "url": "https://finnhub.io/api/news?id=bc456e33e15cf76dcaa8b97d53d4313285e1d1e774bdc8090f51d5d1802a753a"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo Therapeutics Shares Drop 55% After Termination of Pfizer Deal",
    "summary": "Sangamo Therapeutics Shares Drop 55% After Termination of Pfizer Deal",
    "url": "https://finnhub.io/api/news?id=0a4608e9cb05e063949cfc258e8dcf6047ab5d23a4d6388949d17cbf294fb4a7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735581780,
      "headline": "Sangamo Therapeutics Shares Drop 55% After Termination of Pfizer Deal",
      "id": 132323922,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Sangamo Therapeutics Shares Drop 55% After Termination of Pfizer Deal",
      "url": "https://finnhub.io/api/news?id=0a4608e9cb05e063949cfc258e8dcf6047ab5d23a4d6388949d17cbf294fb4a7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Ends Sangamo Partnership for Hemophilia Therapy",
    "summary": "By Katherine Hamilton Sangamo Therapeutics said it will regain rights to develop and commercialize a therapy for hemophilia A after Pfizer terminated their collaboration and license agreement. ...",
    "url": "https://finnhub.io/api/news?id=57a9ac89192957e5f9c04c168d106974ac906d3e2e59c82958ccb0fe3c4b1f6d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735578073,
      "headline": "Pfizer Ends Sangamo Partnership for Hemophilia Therapy",
      "id": 132206183,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Katherine Hamilton Sangamo Therapeutics said it will regain rights to develop and commercialize a therapy for hemophilia A after Pfizer terminated their collaboration and license agreement. ...",
      "url": "https://finnhub.io/api/news?id=57a9ac89192957e5f9c04c168d106974ac906d3e2e59c82958ccb0fe3c4b1f6d"
    }
  },
  {
    "ts": null,
    "headline": "Beaten Down Biogen Stock Looks Attractive At Current Levels",
    "summary": "The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments. Click here to read I rate BIIB a Buy.",
    "url": "https://finnhub.io/api/news?id=9d2f84f3c5cf32361741ae09e904d063b6c6bf280e774c53c963c02299824733",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735565867,
      "headline": "Beaten Down Biogen Stock Looks Attractive At Current Levels",
      "id": 132204159,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165724853/image_2165724853.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments. Click here to read I rate BIIB a Buy.",
      "url": "https://finnhub.io/api/news?id=9d2f84f3c5cf32361741ae09e904d063b6c6bf280e774c53c963c02299824733"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: One Of The Next Big AI Winners",
    "summary": "Why Kirk Spano sees Pfizer as one of the next big winners from AI and why he thinks investors should be selling cash secured puts.",
    "url": "https://finnhub.io/api/news?id=dd76e4f143a6f7d8bc0b662d8b05abb521cdce407f284b021a8fd3ca866a330c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735560000,
      "headline": "Pfizer: One Of The Next Big AI Winners",
      "id": 132203251,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341266246/image_1341266246.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Why Kirk Spano sees Pfizer as one of the next big winners from AI and why he thinks investors should be selling cash secured puts.",
      "url": "https://finnhub.io/api/news?id=dd76e4f143a6f7d8bc0b662d8b05abb521cdce407f284b021a8fd3ca866a330c"
    }
  },
  {
    "ts": null,
    "headline": "Drug Middlemen Spared by Trump and Musk, for Now",
    "summary": "Tucked into the bipartisan budget deal that President-elect  Donald Trump’s  allies torpedoed earlier this month was a rare and significant attempt to reform the mechanics of America’s drug-pricing system.  Americans are broadly aware of how big pharma profits from high drug prices, but few understand the market distortions introduced by pharmacy benefit management (PBM) companies that negotiate prices on behalf of employers, insurers and government programs.",
    "url": "https://finnhub.io/api/news?id=f46b69a891dc4086d7e9df1c9af657770eebe7d7eae3125bd692a48e06dede5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735554600,
      "headline": "Drug Middlemen Spared by Trump and Musk, for Now",
      "id": 132201376,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Tucked into the bipartisan budget deal that President-elect  Donald Trump’s  allies torpedoed earlier this month was a rare and significant attempt to reform the mechanics of America’s drug-pricing system.  Americans are broadly aware of how big pharma profits from high drug prices, but few understand the market distortions introduced by pharmacy benefit management (PBM) companies that negotiate prices on behalf of employers, insurers and government programs.",
      "url": "https://finnhub.io/api/news?id=f46b69a891dc4086d7e9df1c9af657770eebe7d7eae3125bd692a48e06dede5d"
    }
  },
  {
    "ts": null,
    "headline": "5 Unbeatable Stocks I'm Eager to Buy in 2025",
    "summary": "These value, growth, and income stocks are incredibly cheap in a historically pricey stock market.",
    "url": "https://finnhub.io/api/news?id=e0145fcf2cc62d0c98c2de1e689052f1e35a62b1362f114df4682194c83fb314",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735553160,
      "headline": "5 Unbeatable Stocks I'm Eager to Buy in 2025",
      "id": 132201377,
      "image": "https://g.foolcdn.com/editorial/images/802213/stopwatch-second-hand-time-to-buy-invest-stock-market-getty.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These value, growth, and income stocks are incredibly cheap in a historically pricey stock market.",
      "url": "https://finnhub.io/api/news?id=e0145fcf2cc62d0c98c2de1e689052f1e35a62b1362f114df4682194c83fb314"
    }
  },
  {
    "ts": null,
    "headline": "My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks",
    "summary": "Learn how the power of dividend growth investing and how commitment and a long-term mindset can help you reach your financial goals in this article. Click for more.",
    "url": "https://finnhub.io/api/news?id=36b35b5a54d061f97391d1ec47bcbdd058d712842641076ec316d1e71e3da642",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735552838,
      "headline": "My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks",
      "id": 132202626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153983350/image_2153983350.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Learn how the power of dividend growth investing and how commitment and a long-term mindset can help you reach your financial goals in this article. Click for more.",
      "url": "https://finnhub.io/api/news?id=36b35b5a54d061f97391d1ec47bcbdd058d712842641076ec316d1e71e3da642"
    }
  },
  {
    "ts": null,
    "headline": "My 5 Favorite Ultra-High-Yield Dividend Stocks to Buy for 2025",
    "summary": "Investing in stocks allows me to own portions of great businesses.  Dividends pay me to own the stocks.  Here are my five favorite ultra-high-yield dividend stocks to buy for 2025 (listed alphabetically).",
    "url": "https://finnhub.io/api/news?id=39c84f914694fd0120f970b935dec57e40f8aaccf3d057019bf8e06494cc9820",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735549440,
      "headline": "My 5 Favorite Ultra-High-Yield Dividend Stocks to Buy for 2025",
      "id": 132200936,
      "image": "https://g.foolcdn.com/editorial/images/802241/pipeline-welder.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing in stocks allows me to own portions of great businesses.  Dividends pay me to own the stocks.  Here are my five favorite ultra-high-yield dividend stocks to buy for 2025 (listed alphabetically).",
      "url": "https://finnhub.io/api/news?id=39c84f914694fd0120f970b935dec57e40f8aaccf3d057019bf8e06494cc9820"
    }
  }
]